|
In Jersey Drug Watch, Joseph D'Orazio, MD, an addiction medicine physician and expert toxicologist, breaks down current trends in the drug landscape for health care providers in the Garden State.
Illicitly manufactured fentanyl remains the dominant opioid in the U.S. drug supply and the primary driver of fatal opioid overdoses. However, an evolving group of highly potent, non-fentanyl synthetic opioids—including nitazenes and, more recently, orphines—is increasingly being detected, adding new complexity to an already unpredictable illicit drug supply.
Nitazenes are a family of non-fentanyl benzimidazole opioids first identified in the U.S. illicit drug supply in 2019. Detections expanded substantially through 2024, with newer analogues such as metonitazene and protonitazene replacing earlier compounds such as isotonitazene. Nitazenes are frequently found alongside fentanyl and other drugs rather than as standalone products, emphasizing that they currently represent an infiltration of a fentanyl-dominant supply rather than a replacement for fentanyl.
More recently, another class of highly potent synthetic opioids known as orphines has emerged. These include brorphine, chlorphine, spirochlorphine, and N-propionitrile chlorphine (cychlorphine). Following regulatory control of nitazenes in China in July 2025, CFSRE surveillance has shown declining nitazene positivity alongside increasing orphine detections, suggesting another potential shift in the illicit opioid supply.
Cychlorphine is of particular concern, with in vitro data suggesting potency approximately 10-fold greater than fentanyl and increasing detection in fatal overdoses since mid-2025. Confirmed cases have been identified across multiple U.S. states, including neighboring Pennsylvania. While these substances remain uncommon and their presence in the drug supply is unpredictable, their emergence demonstrates the continued evolution of the illicit opioid landscape.
For clinicians, the treatment of opioid overdose has not changed. Regardless of whether the opioid involved is fentanyl, carfentanil, a nitazene, an orphine, or another synthetic opioid, naloxone remains highly effective at reversing opioid-induced respiratory depression.
|